Ligand id: 6840

Name: pralatrexate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 12
Hydrogen bond donors 5
Rotatable bonds 11
Topological polar surface area 207.3
Molecular weight 477.18
XLogP -0.63
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat relapsed or refractory peripheral T-cell lymphoma. Refused EMA full approval (June 2012), but retains orphan designation for four indications.
Mechanism Of Action and Pharmacodynamic Effects
Impairs the cancer cell's ability to synthesise DNA and RNA resulting in apoptosis. More efficiently retained in cancer cells than methotrexate.
External links